| Identification | Back Directory | [Name]
Benzamide, N-[3-[[(3S)-3-amino-1-piperidinyl]methyl]-5-(4-methyl-1H-imidazol-1-yl)phenyl]-4-methyl-3-phenoxy- | [CAS]
2244129-23-3 | [Synonyms]
PCSK9-IN-13
Benzamide, N-[3-[[(3S)-3-amino-1-piperidinyl]methyl]-5-(4-methyl-1H-imidazol-1-yl)phenyl]-4-methyl-3-phenoxy- | [Molecular Formula]
C30H33N5O2 | [MOL File]
2244129-23-3.mol | [Molecular Weight]
495.62 |
| Chemical Properties | Back Directory | [Boiling point ]
624.6±55.0 °C(Predicted) | [density ]
1.23±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
13.26±0.70(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
PCSK9-IN-13(compound 3f) is a potent PCSK9 inhibitor, which can antagonize low-density lipoprotein (LDL) receptor binding by binding to PCSK9, with an IC50 of 537 nM[1]. | [in vivo]
PCSK9-IN-13(compound 3f) (3.28 or 16.4 mg/kg/day, s.c., 14 days) in male C57BL/6 mice dose not show a reduction in total cholesterol at a dose of 3.28 mg/kg, however, a dose of 16.4 mg/kg shows a significant reduction of total cholesterol plasma levels by approximately 10%, and exhibits excellent bioavailability[1].
The pharmacokinetic parameters of PCSK9-IN-13(compound 3f) in C57BL/6 mice
| Parameter | SC | PO | IV(single) | IV(cassette) | |
| Dose(mg/kg) | 20 | 20 | 5 | 0.4 | | Tmax(h) | 1 | 2 | - | - | |
| Cmax(ng/mL) | 2207 | 52.6 | - | - | |
| CL(L/h/kg) | - | - | 1.09 | 0.3 | |
| Vss(L/kg) | - | - | 3.87 | 9.13 | |
| T1/2(h) | 5.47 | - | 9.86 | 25.7 | |
| AUC∞(h*ng/mL) | 16811 | - | 4605 | 1472 | |
| MRT∞(h) | - | - | 3.56 | 34.9 | |
| F(%) | 91.3 | 0.527 | - | - | |
| [References]
[1] Benny J.?Evison, et al. A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove.Bioorganic & Medicinal Chemistry |
|
|